In this real-world cohort, both metastatic site and burden strongly influenced response and survival of avelumab. Bone metastases were independently associated with poor prognosis, while nodal-only disease identified a favorable subgroup. These findings support risk-based treatment stratification in the maintenance setting.
Roviello et al. (Sat,) studied this question.